- Home
- DSL vs NRIX Comparison
DSL vs NRIX Comparison
Compare DSL & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- NRIX
- Stock Information
- Founded
- DSL 2013
- NRIX 2009
- Country
- DSL United States
- NRIX United States
- Employees
- DSL N/A
- NRIX N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- NRIX Health Care
- Exchange
- DSL Nasdaq
- NRIX Nasdaq
- Market Cap
- DSL 1.3B
- NRIX 1.1B
- IPO Year
- DSL N/A
- NRIX 2020
- Fundamental
- Price
- DSL $11.94
- NRIX $11.56
- Analyst Decision
- DSL
- NRIX Strong Buy
- Analyst Count
- DSL 0
- NRIX 17
- Target Price
- DSL N/A
- NRIX $30.71
- AVG Volume (30 Days)
- DSL 728.4K
- NRIX 1.3M
- Earning Date
- DSL 01-01-0001
- NRIX 04-08-2025
- Dividend Yield
- DSL 11.06%
- NRIX N/A
- EPS Growth
- DSL N/A
- NRIX N/A
- EPS
- DSL N/A
- NRIX N/A
- Revenue
- DSL N/A
- NRIX $56,417,000.00
- Revenue This Year
- DSL N/A
- NRIX $12.84
- Revenue Next Year
- DSL N/A
- NRIX N/A
- P/E Ratio
- DSL N/A
- NRIX N/A
- Revenue Growth
- DSL N/A
- NRIX N/A
- 52 Week Low
- DSL $10.58
- NRIX $8.18
- 52 Week High
- DSL $13.24
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- DSL 49.70
- NRIX 51.19
- Support Level
- DSL $11.44
- NRIX $9.23
- Resistance Level
- DSL $11.76
- NRIX $12.38
- Average True Range (ATR)
- DSL 0.29
- NRIX 0.95
- MACD
- DSL 0.05
- NRIX 0.42
- Stochastic Oscillator
- DSL 97.84
- NRIX 80.48
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.